Frank Mottola compensation by year
SUPERNUS PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $352,700 | $377,400 | $412,500 |
| Bonus | $0 | — | $0 |
| Stock awards | $544,500 | $341,525 | $315,040 |
| Option awards | $715,200 | $432,254 | $411,214 |
| Non-equity incentive | $129,361 | $140,001 | $173,910 |
| Pension and deferred compensation | $0 | — | $0 |
| All other | $44,418 | $43,765 | $48,037 |
| Total | $1,786,179 | $1,334,945 | $1,360,701 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SUPERNUS PHARMACEUTICALS, INC. DEF 14A filed April 30, 2026, accession 0001104659-26-053111, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 5,000 | $248,500 | — |
| PSU | 3,750 | $186,375 | — |
| RSU | 3,750 | $186,375 | — |
| RSU | 750 | $37,275 | — |
| Option | 4,500 | — | $32.20 |
| Option | 18,750 | — | $27.94 |
| Option | 15,000 | — | $38.60 |
| Option | 20,000 | — | $33.52 |
Per the Outstanding Equity Awards at Fiscal Year-End table in SUPERNUS PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed April 30, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-12 | Tax withholding | — | 797 | $46.57 | 19,544 |
| 2026-08-12 | Exercise or conversion derivative | — | 1,650 | $0.00 | 0 |
| 2026-08-12 | Exercise or conversion | — | 1,650 | $0.00 | 20,341 |
| 2026-07-29 | Grant or award derivative | — | 1,650 | $0.00 | 1,650 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments SUPERNUS PHARMACEUTICALS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Resignation for good reason, no change in control | $412,500 | $0 | $35,425 | $587,926 |
| Involuntary termination without cause | $412,500 | $0 | $35,425 | $587,926 |
| Change in control and resignation for good reason | $412,500 | $3,983,225 | $35,425 | $4,571,151 |
Per the Potential Payments Upon Termination or Change in Control table in SUPERNUS PHARMACEUTICALS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
SUPERNUS PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jack Khattar | Chief Executive Officer, President & Secretary | $15,501,557 |
| Timothy Dec | Senior Vice President, Chief Financial Officer | $1,916,409 |
| Jonathan Rubin | Senior Vice President, Chief Medical Officer, Research and Development | $1,448,731 |
| Padmanabh Bhatt | Senior Vice President of Intellectual Property, Chief Scientific Officer | $1,391,429 |
| Frank Mottola · this page | Senior Vice President, Chief Technical Operations Officer | $1,360,701 |
The full SUPERNUS PHARMACEUTICALS compensation record
free company briefThis page is one person within SUPERNUS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order SUPERNUS PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SUPERNUS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat